Norge - norsk - Statens legemiddelverk

glaxosmithkline as - salmeterolxinafoat - inhalasjonsaerosol, suspensjon - 25 mikrog/ dose

Norge - norsk - Statens legemiddelverk

glaxosmithkline as - salmeterolxinafoat - inhalasjonspulver, dosedispensert - 50 mikrog/ dose

Norge - norsk - Statens legemiddelverk

orifarm as - salmeterolxinafoat - inhalasjonsaerosol, suspensjon - 25 mikrog/ dose

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - maksimalt tre av følgende renset, inaktivert fot-og-munn sykdom virusartene: o1 manisa ≥ 6 pd50*; o1 bfs ≥ 6 pd50*; o taiwan 3/97 ≥ 6 pd50*; a22 irak ≥ 6 pd50*; a24 cruzeiro ≥ 6 pd50*; en kalkun 14/98 ≥ 6 pd50*; asia 1 shamir ≥ 6 pd50*; sat2 saudi-arabia ≥ 6 pd50*; * pd50 – 50% beskyttende dose i storfe som er beskrevet i tlf. eur. monografi 0063. - immunologicals - pigs; cattle; sheep - aktiv immunisering av storfe, sauer og griser fra 2 ukers alder mot munn- og klovsyke for å redusere kliniske tegn.

Den europeiske union - norsk - EMA (European Medicines Agency)

laboratoire hra pharma - ulipristal - prevensjon, postcoital - sex hormoner og modulatorer av genital systemet, , nødprevensjon - nødpreventjon innen 120 timer (fem dager) av ubeskyttet samleie eller prevensjonsfeil.

Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - apixaban - venous thromboembolism; stroke; arthroplasty - antithrombotic agents - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery. forebygging av slag og systemisk emboli hos voksne pasienter med ikke-valvulær atrieflimmer (nvaf), med én eller flere risikofaktorer, slik som tidligere hjerneslag eller forbigående ischaemic angrep (tia); alder ≥ 75 år, hypertensjon; diabetes mellitus; symptomatisk hjertesvikt (nyha klasse ≥ ii). behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne (se kapittel 4. 4 for haemodynamically ustabil pe pasienter). prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii). behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne (se kapittel 4. 4 for haemodynamically ustabil pe pasienter).

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Den europeiske union - norsk - EMA (European Medicines Agency)

chemical works of gedeon richter plc. (gedeon richter plc.) - ganirelix acetate - reproductive techniques, assisted; ovulation induction; infertility, female - hypofysiske og hypotalamiske hormoner og analoger - prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).

Den europeiske union - norsk - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaksiner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Den europeiske union - norsk - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaksiner - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.